• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

研究不同预后危险因素的胆管癌患者群体在转录和免疫方面的差异。

Investigation of transcriptional and immunological disparities among patient groups with varied prognostic risk factors in cholangiocarcinoma.

机构信息

Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Thorgene Co., Ltd., Beijing, China.

出版信息

Cancer Med. 2024 Aug;13(16):e70135. doi: 10.1002/cam4.70135.

DOI:10.1002/cam4.70135
PMID:39206584
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11358702/
Abstract

BACKGROUND

This study explores molecular features associated with better prognosis in cholangiocarcinoma (CCA).

METHODS AND RESULTS

The transcriptomic and whole-exome sequencing data obtained from paired tissues of 70 were analyzed, grouping them based on progression-free survival (PFS), differentiation degree, and lymph node metastasis. Among the 70 patients, the TP53 gene mutation frequency was the highest (53%), while FLG gene mutation occurred exclusively in the long PFS group. In the comparison between long and short survival groups, the short PFS group exhibited higher monocyte infiltration levels (p = 0.0287) and upregulation of genes associated with cancer-related transcriptional misregulation, chemokine signaling, and cytokine-cytokine receptor interactions. Differences in immune cell infiltration and gene expression were significant across differentiation and lymph node metastasis groups. Particularly noteworthy was the marked increase in CD8 T cell and NK cell infiltration (p = 0.0291, 0.0459) in the lymph node metastasis group, significantly influences prognosis. Additionally, genes related to platinum resistance, Th17 cell differentiation, and Th1 and Th2 cell differentiation pathways were overexpressed in this group. In summary, higher monocyte infiltration levels in the short PFS group, along with elevated expression of genes associated with cancer-related pathways, suggest a poorer prognosis. The significant increase in CD8 T cell and NK cell infiltration reflects an enhanced anti-tumor immune response, underscoring the relevance of immune infiltration levels and gene expression in predicting outcomes for CCA patients.

CONCLUSIONS

In this study, we elucidated the pertinent molecular mechanisms and pathways that influence the prognosis of CCAs through comprehensive multi-omics analysis.

摘要

背景

本研究探讨了与胆管癌(CCA)预后较好相关的分子特征。

方法和结果

分析了从 70 对组织中获得的转录组和全外显子测序数据,根据无进展生存期(PFS)、分化程度和淋巴结转移对其进行分组。在这 70 名患者中,TP53 基因突变频率最高(53%),而 FLG 基因突变仅发生在长 PFS 组。在长生存组和短生存组之间的比较中,短 PFS 组表现出更高的单核细胞浸润水平(p=0.0287),并且与癌症相关转录失调、趋化因子信号和细胞因子-细胞因子受体相互作用相关的基因上调。在分化和淋巴结转移组之间,免疫细胞浸润和基因表达的差异具有统计学意义。特别值得注意的是,淋巴结转移组的 CD8 T 细胞和 NK 细胞浸润显著增加(p=0.0291,0.0459),这对预后有显著影响。此外,该组中与铂类耐药、Th17 细胞分化以及 Th1 和 Th2 细胞分化途径相关的基因表达上调。总之,短 PFS 组中单核细胞浸润水平较高,以及与癌症相关途径相关基因的表达上调,提示预后较差。CD8 T 细胞和 NK 细胞浸润的显著增加反映了增强的抗肿瘤免疫反应,强调了免疫浸润水平和基因表达在预测 CCA 患者预后中的相关性。

结论

在这项研究中,我们通过综合多组学分析阐明了影响 CCA 预后的相关分子机制和途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d5/11358702/a96212cb4083/CAM4-13-e70135-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d5/11358702/cde10f1b6214/CAM4-13-e70135-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d5/11358702/dd77e94fd313/CAM4-13-e70135-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d5/11358702/a97e0a2376e9/CAM4-13-e70135-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d5/11358702/a96212cb4083/CAM4-13-e70135-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d5/11358702/cde10f1b6214/CAM4-13-e70135-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d5/11358702/dd77e94fd313/CAM4-13-e70135-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d5/11358702/a97e0a2376e9/CAM4-13-e70135-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d5/11358702/a96212cb4083/CAM4-13-e70135-g004.jpg

相似文献

1
Investigation of transcriptional and immunological disparities among patient groups with varied prognostic risk factors in cholangiocarcinoma.研究不同预后危险因素的胆管癌患者群体在转录和免疫方面的差异。
Cancer Med. 2024 Aug;13(16):e70135. doi: 10.1002/cam4.70135.
2
Oncostatin M expression and mutation status regulate tumor-infiltration of immune cells and survival outcomes in cholangiocarcinoma.抑瘤素 M 的表达和突变状态调节胆管癌肿瘤浸润免疫细胞和生存结局。
Aging (Albany NY). 2020 Nov 7;12(21):21518-21543. doi: 10.18632/aging.103936.
3
PNOC Expressed by B Cells in Cholangiocarcinoma Was Survival Related and LAIR2 Could Be a T Cell Exhaustion Biomarker in Tumor Microenvironment: Characterization of Immune Microenvironment Combining Single-Cell and Bulk Sequencing Technology.胆管癌中 B 细胞表达的 PNOC 与生存相关,而 LAIR2 可能是肿瘤微环境中 T 细胞耗竭的生物标志物:单细胞和批量测序技术联合分析免疫微环境。
Front Immunol. 2021 Mar 24;12:647209. doi: 10.3389/fimmu.2021.647209. eCollection 2021.
4
Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.转录组谱分析鉴定 TIGIT 为肝癌 T 细胞耗竭的标志物。
Hepatology. 2021 Apr;73(4):1399-1418. doi: 10.1002/hep.31466.
5
Expression and clinical significance of interleukin-6 pathway in cholangiocarcinoma.胆管癌中白细胞介素-6 通路的表达及临床意义。
Front Immunol. 2024 May 31;15:1374967. doi: 10.3389/fimmu.2024.1374967. eCollection 2024.
6
Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.爱泼斯坦-巴尔病毒相关肝内胆管癌的临床病理特征、肿瘤免疫微环境及基因组格局
J Hepatol. 2021 Apr;74(4):838-849. doi: 10.1016/j.jhep.2020.10.037. Epub 2020 Nov 17.
7
Identification of a novel mutation gene signature HAMP for cholangiocarcinoma through comprehensive TCGA and GEO data mining.通过全面的 TCGA 和 GEO 数据挖掘鉴定胆管癌的新型突变基因特征 HAMP。
Int Immunopharmacol. 2021 Oct;99:108039. doi: 10.1016/j.intimp.2021.108039. Epub 2021 Aug 12.
8
Aberrant expression of B7-H4 correlates with poor prognosis and suppresses tumor-infiltration of CD8+ T lymphocytes in human cholangiocarcinoma.B7-H4 的异常表达与不良预后相关,并抑制人胆管癌中 CD8+T 淋巴细胞的浸润。
Oncol Rep. 2016 Jul;36(1):419-27. doi: 10.3892/or.2016.4807. Epub 2016 May 13.
9
Integrative multi-omics analysis reveals the role of tumor-associated endothelial cells and their signature in prognosis of intrahepatic cholangiocarcinoma.整合多组学分析揭示肿瘤相关内皮细胞及其特征在肝内胆管癌预后中的作用。
J Transl Med. 2024 Oct 19;22(1):948. doi: 10.1186/s12967-024-05750-2.
10
Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.全面分析基因组突变特征和肿瘤突变负担对肝内胆管癌预后的影响。
BMC Cancer. 2021 Feb 3;21(1):112. doi: 10.1186/s12885-021-07788-7.

本文引用的文献

1
Efficacy and safety of subsequent radiotherapy in patients with advanced-stage hepatocellular carcinoma treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗的晚期肝细胞癌患者后续放疗的疗效和安全性
Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):882-897. doi: 10.21037/hbsn-23-134. Epub 2023 May 31.
2
Cell death checkpoints in the TNF pathway.肿瘤坏死因子通路中的细胞死亡检查点。
Trends Immunol. 2023 Aug;44(8):628-643. doi: 10.1016/j.it.2023.05.007. Epub 2023 Jun 23.
3
Cholangiocarcinoma: a review of the literature and future directions in therapy.
胆管癌:文献综述与治疗的未来方向
Hepatobiliary Surg Nutr. 2022 Aug;11(4):555-566. doi: 10.21037/hbsn-20-396.
4
Current epidemiology of cholangiocarcinoma in Western countries.西方国家胆管癌的当前流行病学。
J Hepatol. 2022 Dec;77(6):1690-1698. doi: 10.1016/j.jhep.2022.07.022. Epub 2022 Aug 14.
5
Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review.胆管癌中的新型生物标志物与靶向治疗的未来:一篇叙述性综述
Hepatobiliary Surg Nutr. 2022 Apr;11(2):253-266. doi: 10.21037/hbsn-20-475.
6
Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance.核糖体生物发生:癌症转移和治疗抵抗的核心参与者。
Cancer Res. 2022 Jul 5;82(13):2344-2353. doi: 10.1158/0008-5472.CAN-21-4087.
7
Emerging Role of cAMP/AMPK Signaling.cAMP/AMPK 信号通路的新作用。
Cells. 2022 Jan 17;11(2):308. doi: 10.3390/cells11020308.
8
Cholangiocarcinoma.胆管癌。
Nat Rev Dis Primers. 2021 Sep 9;7(1):65. doi: 10.1038/s41572-021-00300-2.
9
Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer.肿瘤内异质性作为非小细胞肺癌抗PD-(L)1治疗中的预测生物标志物。
Mol Cancer. 2021 Feb 23;20(1):37. doi: 10.1186/s12943-021-01331-9.
10
The association between tumor mutational burden and prognosis is dependent on treatment context.肿瘤突变负担与预后的关联取决于治疗背景。
Nat Genet. 2021 Jan;53(1):11-15. doi: 10.1038/s41588-020-00752-4. Epub 2021 Jan 4.